Summary
Despite the increasing number of patients with metastatic pancreatic adenocarcinoma (mPDAC) receiving second-line chemotherapy, little data have been reported about long-term survivors of mPDAC and prognostic factors. The study analyzes the prognostic variables of mPDAC in patients with a survival of 10 months or longer (long-term survivors). Patients registered in an institutional database receiving chemotherapy for mPDAC were selected, and two models defined the most relevant variables at baseline and after the first cycle of chemotherapy in short- and long-term survivors. A total of 110 patients were included, 69 short- and 41 long-term survivors. At baseline, long-term survivors reported significantly low rates of elevated carbohydrate antigen (CA) 19‑9 (odds ratio [OR] 0.81, confidence interval [CI] 0.67–0.97) and liver involvement (OR 0.35, CI 0.14–0.90). After the first cycle of chemotherapy, polychemotherapy regimens (OR 5.26, CI 1.57–17.67) and neutrophil reduction (OR 0.16, CI 0.03–0.80) were the only independent variables associated with a long-term survivorship. mPDAC long-term survivors rarely present elevated serum CA 19‑9 concentrations or liver metastases at baseline. Although they receive more intensive chemotherapy regimens, they more frequently experienced neutrophil reduction after the first cycle of chemotherapy regardless of the regimen.
Similar content being viewed by others
References
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7–30.
Golan T, Sella T, Margalit O, Amit U, Halpern N, Shacham-Shmueli E, et al. Short- and long-term survival in metastatic pancreatic adenocarcinoma, 1993–2013. J Natl Compr Cancer Netw. 2017;15(8):1022–7.
Conroy T, Desseigne F, Ychou M, Bouchè O, Guimbaud R, Bécouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–25.
Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691–703.
Wang-Gillam A, Li C‑P, Bodoky G, Dean A, Shan Y‑S, Jameson G, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet. 2016;387:545–57.
ter Veer E, van Rijssen LB, Besselink MG, Mali RMA, Berlin JD, Boeck S, et al. Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease. Lancet Oncol. 2018;9(3):e151–e60.
Rochefort P, Lardy-Cleaud A, Sarabi M, Desseigne F, Cattey-Javouhey A, de la Fouchardiere C. Long-term survivors in metastatic pancreatic ductal adenocarcinoma: a retrospective and matched pair analysis. Oncologist. 2019;4:1543–8.
Kowalczyk M, Mandelson MT, Lin BS‑L, Picozzi VJ. Metastatic pancreatic cancer (MPC): contrast of short-(STS) and long-term(LTS) survivor characteristics. J Clin Oncol. 2018;36(suppl 4S):abstract 415.
Gao Y, Wang WJ, Zhi Q, Shen M, Jiang M, Bian X, et al. Neutrophil/lymphocyte ratio is a more sensitive systemic inflammatory response biomarker than platelet/lymphocyte ratio in the prognosis evaluation of unresectable pancreatic cancer. Oncotarget. 2017;8:88835–44.
Goldstein D, El-Maraghi RH, Hammel P, Heinemann V, Kunzmann V, Sastre J, et al. nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. J Natl Cancer Inst. 2015;107(2):dju413.
Colloca GA, Venturino A, Guarneri D. Neutrophil count kinetics during the first cycle of chemotherapy predicts the outcome of patients with locally advanced or metastatic pancreatic cancer. Asia Pac J Clin Oncol. 2020;16(4):247–53.
van der Sijde F, Vietsch EE, Mustafa DAM, Besselinj MG, Koerkamp BG, van Eijck CHJ. Circulating biomarkers for prediction of objective response to chemotherapy in pancreatic cancer patients. Cancers. 2019;11:93.
Yoo T, Lee WJ, Woo SM, Kim TH, Han SS, Park SJ, et al. Pretreatment carbohydrate antigen 19‑9 level indicates tumor response, early distant metastasis, overall survival, and therapeutic selection in localized and unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys. 2011;81:e623–e30.
Cannistrà M, Ruggiero M, Zullo A, Serafini S, Grande R, Nardo B. Metastases of pancreatic adenocarcinoma: a systematic review of literature and a new functional concept. Int J Surg. 2015;21(1):S15–S21.
Zheng B, Ohuchida K, Yan Z, Okumura T, Ohtsuka T, Nakamura M. Primary recurrence in the lung is related to favorable prognosis in patients with pancreatic cancer and postoperative recurrence. World J Surg. 2017;41:2858–66.
Wangjam T, Zhang Z, Zhou XC, Lyer L, Faisal F, Soares KC, et al. Resected pancreatic ductal adenocarcinomas with recurrence limited in lung have a significantly better prognosis than those with other recurrence patterns. Oncotarget. 2015;6(34):36903–10.
Jr Uson PLS, D’Avila Sampaio Tolentino F, Montes Santos V, Rother ET, Maluf FC. The impact of metastatic sites in advanced pancreatic adenocarcinoma, systematic review and meta-analysis of prospective randomized studies. PLoS ONE. 2020; https://doi.org/10.1371/journal.pone.0230060.
Oweira H, Petrausch U, Helbling D, Schmidt J, Mannhart M, Mehrabi A, et al. Prognostic value of site-specific metastases in pancreatic adenocarcinoma: a Surveillance Epidemiology and End Results database analysis. World J Gastroenterol. 2017;23(10):1872–8.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
G.A. Colloca and A. Venturino declare that they have no competing interests.
Ethical standards
All procedures performed in studies involving human participants or on human tissue were in accordance with the ethical standards of the institutional research committee of Regione Liguria and with the 1975 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Data availability
Data will be shared upon reasonable request to the corresponding author.
Rights and permissions
About this article
Cite this article
Colloca, G.A., Venturino, A. Prognostic factors of long-term survivors with unresectable pancreatic cancer: a retrospective analysis. memo 17, 146–151 (2024). https://doi.org/10.1007/s12254-023-00917-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12254-023-00917-x